Innovent Biologics grants 583,731 restricted shares under 2024 share scheme

• Innovent Biologics granted 59,757 share options, exercisable at HK$ 105.76 per share, with a 10-year exercise period.
• It also awarded 583,731 restricted shares, valued at about HK$ 59.31 million using the HK$ 101.60 closing price.
• Most awards vest 75% on Sept. 1, 2029, with the remainder vesting on Sept. 1, 2030.
• Non-executive director Ronald Hao Xi Ede received 1,837 options, 5,206 restricted shares, vesting in three equal tranches through Sept. 1, 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260901-12314523), on September 01, 2026, and is solely responsible for the information contained therein.